Infinity Bio is pleased to announce the release of their MuSIGHT™ mouse autoantibody reactome service offering. Defining an ...

Despite a delay in the platform launch, Nautilus Biotechnology Inc (NAUT) showcases advancements in proteomics and maintains a strong cash position.

Q4 2024 Earnings Call Transcript February 28, 2025 Operator: Good day, and thank you for standing by. Welcome to the Nautilus ...

Q4 2024 Earnings Call Transcript March 3, 2025 Quantum-Si incorporated misses on earnings expectations. Reported EPS is ...

The proteoCHIP LF 48 is a state-of-the-art label-free single-cell proteomics sample preparation solution. Designed for ...

SEATTLE, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial ...

Jeff Hawkins; President and Chief Executive Officer; Quantum-Si Inc Jeff Keyes; Chief Financial Officer; Quantum-Si Inc Good afternoon everyone and thank you for joining us. Earlier today, Quantum-Si ...

Seattle's Nautilus Biotechnology is laying off 16% of workforce, and plans to release its commercial platform in late 2026.

Oxford Nanopore Technologies plc ( OTCPK:ONTTF) Q4 2024 Results Conference Call March 4, 2025 4:30 AM ET Gordon Sanghera - Chief Executive Officer Nick Keher - Chief Financial Officer ...

A basic business principle is that no worker is irreplaceable; that also holds true for most proteins, the cellular factory ...

BOSTON and SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical-stage precision medicine company seeking to unlock the proteome to advance ...

Enabling well-powered studies, absolute quantification, and unlimited content flexibility. GEN spoke with Milad Dagher, PhD, CEO and co-founder of Nomic, about how their nELISA platform is ...